Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2001-2020 of 3,900 trials

Tarlatamab for Extensive Stage Small Cell Lung Cancer

We are testing a new subcutaneous treatment for individuals with extensive stage small cell lung cancer. The goal is to see how well it works compared to current options.

Extensive Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Tozorakimab: Syringe vs. Autoinjector Study

We are comparing how well Tozorakimab works when given through a prefilled syringe versus an autoinjector. This study aims to understand the differences in how the body absorbs the medication.

InflammationRespiratory Issues6-12 monthsSafety phase (I)Pulmonology

Unresectable Malignant Mesothelioma: Tremelimumab Study

We are comparing a new treatment called tremelimumab to a placebo for patients with unresectable malignant mesothelioma. The goal is to see if it improves survival and overall health outcomes.

Malignant Mesothelioma>2 yearsEfficacy phase (II)Investigational MedicinesOncology

Cognitive Disorders: BioFINDER 2 Study

We are investigating new imaging methods to better diagnose Alzheimer's disease in healthy older adults and those with early cognitive symptoms. The goal is to understand brain changes that may lead to dementia.

Dementia and Neurodegenerative Disorders>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

B Cell Lymphoma: CAR20(NAP)-T Therapy

We are evaluating a new CAR-T cell therapy for patients with relapsed or refractory B cell lymphoma. The study aims to assess its safety and effectiveness in treating this condition.

Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)Oncology

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Temozolomide for Non-enhancing Adult Brainstem Gliomas

We are studying the effects of Temozolomide chemotherapy in adults with specific types of brainstem gliomas. This trial aims to see how well it works for tumors that show an infiltrative pattern of growth.

Malignant GliomaBrain Stem Glioma>2 yearsEfficacy phase (II)NeurologyOncology

Baricitinib for Calcium Pyrophosphate Disease

We are studying whether Baricitinib can reduce inflammation and improve symptoms in people with calcium pyrophosphate dihydrate deposition disease. This trial will help us understand its effects on pain and inflammation.

Calcium Pyrophosphate Deposition Disease3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Severe Infections in ICU: Comparing Antibiotics

We are studying whether piperacillin-tazobactam or temocillin can effectively treat severe infections caused by certain bacteria in ICU patients, compared to standard carbapenem treatment. This research may help improve treatment options for critically ill patients.

ESBL-Producing Bacteria Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Type 1 Diabetes: Metformin's Impact on Arterial Health

We are studying whether metformin can slow down artery calcification and improve blood flow in people with type 1 diabetes who do not have chronic kidney disease. This research may help us understand how to better manage cardiovascular risks in these patients.

Vascular CalcificationType 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyEndocrinologyInternal Medicine

Antisynthetase Syndrome: Cyclophosphamide vs Tacrolimus

We are comparing the effects of Cyclophosphamide and Azathioprine against Tacrolimus in patients with antisynthetase syndrome-related lung disease. The goal is to see which treatment better improves lung function and quality of life.

Interstitial Lung DiseaseConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Fecal Microbiota Transfer for Diabetes Control After Bariatric Surgery

We are studying whether fecal microbiota transfer can help improve blood sugar levels in patients who had bariatric surgery and are in diabetes remission. This trial will explore its effects on insulin production and overall health.

Type 2 Diabetes>2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyInternal Medicine

Tremelimumab Injection for Early-Stage Lung Cancer

We are studying a new injection method for delivering tremelimumab to patients with early-stage non-small cell lung cancer. The goal is to evaluate its safety and how well it works in the body.

Non-small cell lung cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Prurigo Nodularis: Povorcitinib Treatment Study

We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.

Prurigo Nodularis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Recurrent Solid Tumors: OBT076 Treatment Study

We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.

Malignant Solid Tumor1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Macular Telangiectasia Type 1: Aflibercept vs. Placebo

We are studying whether aflibercept can improve retinal thickness and vision in patients with macular telangiectasia type 1 compared to a placebo. The trial also looks at the safety of the treatment.

Macular Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesOphthalmology

COPD Exacerbation: New Diagnostic Strategy

We are testing a new method using advanced diagnostics to see if it can help reduce antibiotic use during severe COPD flare-ups. This study compares this approach to standard treatment to evaluate its effectiveness and safety.

Severe COPD with Ventilation Support>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPulmonology

Dermatomyositis: Baricitinib Treatment Study

We are studying whether baricitinib can help patients with dermatomyositis improve without using steroids. This trial compares its effects to a placebo while providing usual care.

Dermatomyositis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesDermatologyRheumatology

Relapsed Primary CNS Lymphoma: High-Dose Methotrexate with Glucarpidase

We are exploring a new treatment approach for patients with relapsed primary CNS lymphoma. This study aims to assess the safety of combining high-dose methotrexate with glucarpidase.

Primary Central Nervous System Lymphoma>2 yearsSafety phase (I)Oncology

Pancreatic Cancer: FOLFOX vs. Gemcitabine

We are comparing two chemotherapy treatments, FOLFOX and gemcitabine, for patients with advanced pancreatic cancer who cannot tolerate a stronger regimen. The goal is to see which treatment works better and is safer for these patients.

Pancreatic Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology